News
1d
Verywell Health on MSNNot Enough Adults Are Getting the RSV Vaccine. Here's Why That Matters“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...
13d
Medpage Today on MSNCDC Follows Advice of Ousted Vaccine Panel, Expands Access to RSV ShotThe new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...
The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...
The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...
5d
HealthDay on MSNCDC Now Recommends RSV Vaccine for Some Adults Aged 50 Years and OlderThe CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...
In June, infectious disease physicians sounded the alarm over the Trump administration overstepping existing, transparent processes for changing vaccine recommendations, particularly pointing to new ...
13d
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing vaccine recommendations and assessing whether people receive too ...
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and 59 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results